Boston, MA - The 2023 BIO International Convention was held in Boston, USA during June 5-8. As the most influential biotech industry annual conference in the world and the first edition after Covid-19 pandemic, this year’s conference attracted over 4,000 companies from 85 countries and more than 25,000 visitors. The unprecedented attendance indicated an extraordinary resurgence that the biotech industry is currently experiencing. As a global biotech focusing on the development of innovative drugs for central nervous system (CNS) diseases, NeuShen Therapeutics (the “Company”) participated in a series of events concurrent with the conference, and discussed innovations and collaborations with many industry leaders, partners, and investors.

On June 4, the Company was invited to the "2023 China Focus" conference jointly sponsored by several industry organizations. Founder and CEO of the Company, Dr. Huaqiong Shen, joined the roundtable discussion on the topic of international cooperation for Chinese biopharmaceutical companies and shared success stories. Since its inception, NeuShen has always based itself on a vision of global collaborations, standards, and talents, which put us on the right path to becoming a leading force in CNS drug development.

On June 5, Dr. Huaqiong Shen participated in the "Global Biopharma Cross-Border Summit" organized by Jones Day and MSQ Ventures. As moderator for the panel “Collaborations, Partnerships and Opportunities in CNS Drug Development", Dr. Shen guided an in-depth conversation between a lineup of esteemed guests which included academic experts in the CNS field, such as internationally well-recognized gene therapy researcher Prof. Guangping Gao, business leaders and healthcare-focused investors. During the presentation and networking session, our team gave a detailed company introduction to the attendees and established communication channels with interested parties, highlighting our unique advantages and huge potential in CNS drug development.

On June 7, the Company hosted a cocktail reception at its brand-new Boston R&D Center. The co-hosts included BioAroundWorld, BioCentury and MSQ Ventures. This reception aimed to serve as a relaxing occasion for close friends and partners to exchange ideas during the busy BIO conference and was enthusiastically attended by VIPs such as UMass professor and scientific advisor to the Company, Prof. Guangping Gao, UMass professor and collaborator Prof. Jun Xie, and senior executives and representatives from Neumora, uniQure, Karuna and other CNS-focused biotech companies. In her speech to the guests, Dr. Shen emphasized NeuShen’s core competencies in tackling CNS diseases, namely the adoption of AAV gene therapy and small molecule dual-platform R&D strategy, the assembling of a core international talent team, and the establishment of a focused pipeline from both internal research and external collaboration. NeuShen’s R&D heads, Dr. Lingyun Wu, Dr. Lingzhi Zhao and collaborator Prof. Jun Xie also shared major progress on key current projects. The reception was a remarkable success in inspiring more innovative ideas for future cooperation and discussion.

The 2023 BIO conference was characterized by renewed enthusiasm and confidence in the biotechnology industry and the CNS field, and the desire and efforts of many companies to seek cooperation. NeuShen’s activities during the conference showcased our commitment to the CNS field and our healthy growth trajectory, which received general affirmation and attention from the industry. For example, UMass professor and scientific advisor to the Company, Prof. Guangping Gao, commented that our newly functional R&D facility "has everything needed to conduct gene therapy research and be successful." NeuShen Therapeutics will continue to push forward with current strategies and projects while actively exploring collaboration opportunities with partners in order to realize our goals and fulfill our promises.

About NeuShen

NeuShen Therapeutics is a biotechnology company focusing on innovative drug research and development to address central nervous system disorders, using a dual platform approaches including AAV-based gene therapy and small molecule discovery. With operations both in Shanghai, China and Boston, MA, NeuShen has a world-class team and is honored to be advised by an outstanding Board of Directors and Scientific Advisory Board.